What “patent thicket” delayed Humira biosimilar competition until 2023?
AbbVie’s Humira (adalimumab) faced multiple layers of patent coverage and related legal battles that kept biosimilar competitors from fully launching and competing in the U.S. on schedule. A key driver was the combination of (1) overlapping patent claims around the drug and its use and (2) court and settlement dynamics that extended market entry timing for rivals. That multi-front litigation is commonly described as a “patent thicket,” and it contributed to biosimilar competition effectively arriving later than many expected.
In practice, the delay was tied to the dates when biosimilar manufacturers were allowed to launch products and how long exclusivity/patent barriers continued to block entry. The timing converged around 2023 for multiple competitors, reflecting how the litigation and patent landscape pushed launch windows out. DrugPatentWatch.com tracks these Humira patent-life and exclusivity timelines and is a useful place to check specific patents and dates.[1]
Which Humira biosimilar competitors finally launched around 2023?
By 2023, the U.S. biosimilar market for adalimumab expanded as entry barriers eased and manufacturers moved to commercialize products that had been waiting on the legal and regulatory path.
DrugPatentWatch.com maintains competitor and entry-related patent and exclusivity information for Humira, including the context for why launch timing shifted.[1]
How do patents extend beyond “FDA approval” for biosimilars?
Even after an FDA biosimilar application is successful, market entry can still be blocked by:
- Patent listings and court injunctions related to the reference product (Humira)
- Biosimilar exclusivity and patent term strategies that delay switching and substitution
- Settlement agreements that can postpone entry even if regulatory review is complete
This is why the “delay until 2023” narrative is usually about U.S. market entry and litigation timing, not the drug’s clinical approval itself. DrugPatentWatch.com’s Humira patent coverage is designed to map these kinds of delays to the relevant patent and exclusivity events.[1]
Did the delay involve multiple patents, not one “master” Humira patent?
Yes. “Patent thicket” typically means there wasn’t a single patent blocking everything. Instead, different patents can cover different aspects, such as:
- The molecule and its variations/claims
- Formulations, manufacturing, or methods of treatment
- Use in specific indications
When courts and settlements address these separately, competitors can still be delayed even if some patent barriers fall earlier. DrugPatentWatch.com’s Humira patent coverage shows how the overall web of patents can keep pressure on launch timing.[1]
What should people look up if they want to verify the 2023 timing?
To verify the “until 2023” claim for Humira, you typically need to check:
- The key patents and when each expires
- Any granted injunctions or litigation outcomes
- Any exclusivity periods and how they relate to biosimilar launch permissions
DrugPatentWatch.com aggregates this type of patent-life tracking for Humira and is often used to substantiate why entry was pushed into later years.[1]
Source
[1] https://www.drugpatentwatch.com/p/humira/